Clinical Trial Update: HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP [Phase 2, Phase 3]

View source ↗

Summary

Open-label HELIOS extension study evaluating DISC-1459 (Bitopertin) for safety, tolerability, and efficacy in erythropoietic protoporphyria and X-linked protopo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erythropoietic Protoporphyria
• X-linked Protoporphyria

Drugs mentioned

• Bitopertin (DISC-1459) (bitopertin)

Snippet

Sponsor: Disc Medicine, Inc | Conditions: Erythropoietic Protoporphyria | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION